FOLH1 and prostate carcinoma: Despite the limitations of the survival analyses and the potential for confounders, the consistency of this survival benefit across different disease sites, including liver, which is known to portend worse outcomes for patients with mCPRC,44 strengthens the case for FOLH1 as a prognostic indicator in prostate cancer and may offer valuable insights for risk stratification and treatment planning.